MedTrace Logo

Safety Study of BMS-986202 in Healthy Subjects and to Treat Psoriasis

NCT02763969 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 357

Last updated 2017-08-03

No results posted yet for this study

Summary

The purpose of this study is to establish if BMS-986202 is safe and effective at treating autoimmune diseases such as psoriasis. BMS-986202 which has shown some promise in preclinical studies for inhibiting autoimmune conditions such as psoriasis. This study will be the first time this drug is given to humans.

Conditions

Interventions

DRUG

BMS-986202

DRUG

Placebo

DRUG

Interferon alpha-2a recombinant

DRUG

Famotidine

DRUG

Ustekinumab

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-05-18
Primary Completion
2016-12-15
Completion
2016-12-15

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02763969 on ClinicalTrials.gov